Savara Inc. Stock

Equities

SVRA

US8051111016

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 01:10:26 2024-06-13 pm EDT 5-day change 1st Jan Change
3.995 USD -1.11% Intraday chart for Savara Inc. -0.50% -14.89%
Sales 2024 * - Sales 2025 * 4.9M Capitalization 558M
Net income 2024 * -79M Net income 2025 * -69M EV / Sales 2024 * -
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 114 x
P/E ratio 2024 *
-9.75 x
P/E ratio 2025 *
-9.55 x
Employees 37
Yield 2024 *
-
Yield 2025 *
-
Free-Float 94.37%
More Fundamentals * Assessed data
Dynamic Chart
Oppenheimer Adjusts Savara Price Target to $11 From $9.50, Maintains Outperform Rating MT
Savara Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Dr. Ricky Sun Notifies the Board of Directors of Savara Inc. of His Intention Not to Stand for Reelection CI
Savara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosis at the American Thoracic Society International Conference 2024 CI
Transcript : Savara Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-14-2024 08:00 AM
Savara Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Savara Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Piper Sandler Adjusts Price Target on Savara to $16 From $7, Maintains Overweight Rating MT
JMP Securities Starts Savara With Market Outperform Rating, $8 Price Target MT
Savara Insider Sold Shares Worth $395,900, According to a Recent SEC Filing MT
Savara Insider Sold Shares Worth $442,291, According to a Recent SEC Filing MT
Savara Inc. Introduces Apap Clearpath, A Gm-Csf Autoantibody Blood Test to Detect Autoimmune Pulmonary Alveolar Proteinosis CI
Savara Inc.(NasdaqGS:SVRA) added to NASDAQ Biotechnology Index CI
Savara Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Guggenheim Starts Savara With Buy Rating, $7 Price Target MT
More news
1 day-1.11%
1 week-0.50%
Current month-2.20%
1 month-12.85%
3 months-18.20%
6 months-8.26%
Current year-14.89%
More quotes
1 week
3.86
Extreme 3.86
4.30
1 month
3.84
Extreme 3.84
4.98
Current year
3.84
Extreme 3.84
5.70
1 year
2.60
Extreme 2.6
5.70
3 years
1.02
Extreme 1.02
5.70
5 years
0.69
Extreme 0.69
5.70
10 years
0.69
Extreme 0.69
17.19
More quotes
Managers TitleAgeSince
Chief Executive Officer 53 17-04-26
Director of Finance/CFO 56 17-04-26
Chief Operating Officer 55 23-02-12
Members of the board TitleAgeSince
Director/Board Member 59 17-04-26
Director/Board Member 75 10-09-30
Director/Board Member 56 09-01-31
More insiders
Date Price Change Volume
24-06-13 4 -0.99% 191 388
24-06-12 4.04 -1.70% 667,288
24-06-11 4.11 -1.44% 843,328
24-06-10 4.17 +5.30% 491,164
24-06-07 3.96 -1.49% 1,152,404

Delayed Quote Nasdaq, June 13, 2024 at 12:52 pm EDT

More quotes
Savara Inc. is a clinical-stage biopharmaceutical company, which is focused on rare respiratory diseases. The Company’s lead program, molgramostim nebulizer solution (molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. Molgramostim nebulizer solution is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The Company is engaged in the advancement of the molgramostim aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.
Related indices
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
4.04 USD
Average target price
9 USD
Spread / Average Target
+122.77%
Consensus